Abstracts tagged "clinical trials and systemic lupus erythematosus (SLE)"

Abstract Number: L14 • 2018 ACR/ARHP Annual Meeting
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
Joan T. Merrill¹, Joshua June², Fotios Koumpouras³, Wambui Machua⁴, Mohammad Faisal Khan⁵, Anca Askanase⁶, Arezou Khosroshahi⁷, Saira Sheikh⁸, Paul A. Foster⁹ and Debra J. Zack⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Joshua June, DO, Lansing, MI, ³Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ⁴Internal Medicine, Piedmont Atlanta Hospital, Atlanta, GA, ⁵Arthritis & Rheumatology Center of Oklahoma, PLLC, Oklahoma City, OK, ⁶Director, Columbia University Lupus Center, Columbia University Medical Center, Bronx, NY, ⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁸Medicine, University of North Carolina, Chapel Hill, NC, ⁹Xencor, Inc., San Diego, CA
Background/Purpose: XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgRIIb. Co-ligation of CD19 and FcgRIIb inhibits B lineage cells key to SLE…
Abstract Number: 1047 • 2016 ACR/ARHP Annual Meeting
Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
David Pisetsky¹, Dana Thompson¹, Joseph Wajdula², Annette Diehl² and Sudhakar Sridharan³, ¹Duke University Medical Center and Durham VAMC, Durham, NC, ²Global Product Development, Pfizer Inc, Collegeville, PA, ³PPD Inc, Rockville, MD
Background/Purpose: SLE clinical trials typically require that patients have either a positive ANA serology at a central laboratory during screening or have prior positive…
Abstract Number: 727 • 2015 ACR/ARHP Annual Meeting
Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids
Richard Furie¹, Maya Das², Daner Li², Shanique Smythe², Ericka Mathura² and Patrice Becker², ¹Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ²Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD
Background/Purpose: Melanocortins such as corticotropin and alpha-MSH may modulate steroid-independent immune responses relevant to SLE pathophysiology. We previously reported that repository corticotropin injection (RCI), an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].